Author:
Tamir Tadesse Tarik,Terefe Bewuketu,Wassie Mulugeta,Workneh Belayneh Shetie,Zegeye Alebachew Ferede
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Wantuch PL, Avci FY. Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them. Hum Vaccines Immunotherapeutics. 2018;14(9):2303–9.
2. Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SR et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. The Lancet infectious diseases. 2018;18(11):1191–210.
3. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.
4. Organization WH. Summary of WHO Position Paper on Pneumococcal conjugate vaccines in infants and children under 5 years of age. 2019.
5. Mondiale de la Santé O, Organization WH. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper–February 2019. Wkly Epidemiol Record = Relevé épidémiologique Hebdomadaire. 2019;94(08):85–103. Vaccins antipneumococciques conjugués chez les nourrissons et les enfants de moins de 5 ans: note de synthèse de l’OMS–février 2019.